Etiology:
Trichomonas vaginalis is the etiologic agent of trichomoniasis,
the most common non-viral sexually transmitted disease (STD) in the world.
Transmission: Trichomoniasis is transmitted by sexual
intercourse and transmission via fomites is rare. Epidemiology,
incidence and prevalence: The WHO estimates an incidence of 276
million new cases each year and prevalence of 187 million of infected
individuals. However, the infection is not notifiable.
Pathology/Symptomatology: The T.
vaginalis infection results in a variety of clinical manifestations
- in most cases the patients are asymptomatic, but some may develop signs
typically associated to the disease. Importantly, the main issue concerning
trichomoniasis is its relationship with serious health consequences such as
cancer, adverse pregnancy outcomes, infertility, and HIV acquisition.
Molecular mechanisms of infection: To achieve success
in parasitism trichomonads develop a complex process against the host cells that
includes dependent- and independent-contact mechanisms. This multifactorial
pathogenesis includes molecules such as soluble factors, secreted proteinases,
adhesins, lipophosphoglycan that culminate in cytoadherence and cytotoxicity
against the host cells. Treatment and curability: The
treatment with metronidazole or tinidazole is recommended; however, cure
failures remain problematic due to noncompliance, reinfection and/or lack of
treatment of sexual partners, inaccurate diagnosis, or drug resistance.
Therefore, new therapeutic alternatives are urgently needed.
Protection: Strategies for protection including
sexual behavior, condom usage, and therapy have not contributed to the decrease
on disease prevalence, pointing to the need for innovative approaches. Vaccine
development has been hampered by the lack of long-lasting humoral immunity
associated to the absence of good animal models.